Travere Therapeutics Inc represents values of integrity, innovation, and patient-centricity. With a strong corporate philosophy focused on improving the lives of patients with rare and serious diseases, Travere Therapeutics is committed to delivering transformative therapies. The company places high importance on scientific excellence and collaboration to drive its research and development efforts. By prioritizing the needs of patients and continuously striving for advancements in healthcare, Travere Therapeutics aims to make a meaningful impact in the lives of individuals affected by rare diseases.

Travere Therapeutics Inc is primarily present in multiple countries and regions around the world. The company is focused on providing innovative therapies to patients with rare and serious diseases. With a global presence, Travere Therapeutics operates in key markets such as the United States, Europe, and Canada. Through strategic partnerships and collaborations, the company aims to enhance patient access to its transformative treatments worldwide.

Travere Therapeutics Inc, formerly known as Retrophin Inc, has achieved several significant milestones. Firstly, the company successfully developed and gained approval for its leading product, Sparsentan, a treatment for focal segmental glomerulosclerosis and IgA nephropathy. Additionally, Travere Therapeutics Inc expanded its portfolio through the acquisition of Censa Pharmaceuticals and Orphan Technologies. The company has also demonstrated its commitment to enhancing patient care by partnering with leading research institutions and patient advocacy groups. Furthermore, Travere Therapeutics Inc has continued to invest in research and development to deliver innovative therapies for rare and underserved diseases.

Founded in 1997, Travere Therapeutics Inc is a leading biopharmaceutical company focused on improving the lives of patients with rare and underserved diseases. Formerly known as Retrophin, the company underwent a rebranding in 2019 to reflect its commitment to advancing transformative therapies. With a strong emphasis on innovation, Travere Therapeutics is dedicated to developing and commercializing novel treatments to address critical unmet medical needs. The company's diverse pipeline includes investigational drugs designed to target various diseases, including rare genetic disorders and kidney diseases. Travere Therapeutics Inc continues to build upon its rich history of scientific expertise and collaborations to drive breakthrough solutions for patients worldwide.

The main competitors of Travere Therapeutics Inc in the market include Actelion Pharmaceuticals Ltd, Alexion Pharmaceuticals Inc, and Ultragenyx Pharmaceutical Inc.

Travere Therapeutics Inc is primarily active in the biopharmaceutical industry.

The business model of Travere Therapeutics Inc revolves around developing and commercializing transformative therapies to address rare and serious diseases. By focusing on areas of high unmet medical need, Travere Therapeutics aims to make a meaningful impact on the lives of patients and their families. Leveraging its expertise in research and development, the company strives to identify potential treatment options and deliver innovative solutions to improve patient outcomes. Travere Therapeutics Inc aims to collaborate with healthcare professionals, regulators, and patient advocacy groups to ensure that its therapies reach those who need them the most, providing hope and improving quality of life.

Travere Therapeutics의 P/E 비율은 -2.31입니다.

Travere Therapeutics의 P/S 비율은 2.92입니다.

Travere Therapeutics에 대한 AlleAktien 품질 점수는 5/10입니다.

예상되는 Travere Therapeutics 매출은 228.73 백만 USD입니다.

예상되는 Travere Therapeutics 이익은 -289.15 백만 USD입니다.

Travere Therapeutics Inc is a biotechnology company focused on developing innovative therapies for rare metabolic disorders and kidney diseases. Their business model includes offering products and services in various sectors. One of the key sectors of Travere Therapeutics is drug development. The company is working on developing drug candidates for various diseases, including Mucopolysaccharidosis Type II (MPS II), a rare genetic disorder caused by enzyme deficiencies. Travere Therapeutics has obtained approval for Vimizim and Kyndrisa, the only two approved therapies for MPS II. The company is also developing therapies for other rare metabolic disorders and kidney diseases. Another important sector of Travere Therapeutics is the provision of support services for patients and medical professionals. The company offers training on the treatment of rare metabolic disorders and kidney problems, as well as medical information and assistance with medication procurement. Additionally, the company collaborates closely with patient organizations and other medical institutions to raise awareness about rare diseases. Travere Therapeutics also operates an extensive research and development (R&D) department. Their research focuses on identifying new therapies and drug candidates that have the potential to effectively treat certain diseases. The company's R&D department also invests in clinical trials to assess the effectiveness and safety of their medications and promote the approval of new therapies. Travere Therapeutics also has a strong commitment to collaborating with other companies and organizations in the industry. The company works with scientists and researchers around the world to develop innovative therapies and treatment methods. They also collaborate with regulatory authorities to advance their medications through clinical trials and an effective approval pipeline. The business model of Travere Therapeutics is based on a comprehensive approach to treating rare metabolic disorders and kidney problems. The company offers innovative therapies, support services for patients and medical professionals, and extensive research and development. Through their collaboration with other companies and organizations, Travere Therapeutics aims to realize their vision of better healthcare for all.

Travere Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Travere Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Travere Therapeutics의 ISIN은 US89422G1076입니다.

Travere Therapeutics의 WKN은 A2QHYP입니다.

Travere Therapeutics의 티커는 TVTX입니다.

지난 12개월 동안 Travere Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Travere Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Travere Therapeutics의 현재 배당 수익률은 입니다.

Travere Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Travere Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Travere Therapeutics은 '건강' 섹터에 속합니다.

Travere Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Travere Therapeutics는 0 USD를 배당금으로 지급했습니다.

Travere Therapeutics의 배당금은 USD에 지급됩니다.